Emyria (ASX:EMD)
Broker Briefing Webinar | Michael Winlo, CEO
only | Emyria develops biopharmaceuticals |
guided by Real-WorldData collected | |
usenal | with patients receiving care at our |
clinics | |
1
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
only | Care | ||||||
Patients w | |||||||
unmet needs + | |||||||
new | |||||||
treatments | |||||||
5 clinical sites (Emerald Clinics) treating | ||||
more than 40 complex conditions in | ||||
use | >6,000 patients aged 2-98. | |||
2 | ||||
nal | ||||
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
nal use only
5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.
Data
Insights from
Real-World
Data (RWD)
One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.
3
Emyria is a biotech that, uniquely:
provides care, generates data & develops treatments
nal use only
5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.
Data
Insights from
Real-World
Data (RWD)
One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.
Treatments
Proprietary
drug design +
global
registration
2 FDA-compliant drug development
programs seeking registration with major global regulators. More in development.
4
Emyria's active clinical development programs
Platform | Active programs | Initial opportunities | ||||||||||
onlyuse | ||||||||||||
Ultra-pure | ||||||||||||
Low-doseCBD for | Over-the-counter treatment | |||||||||||
cannabinoid- | EMD | -RX5 | ||||||||||
for psychological distress | ||||||||||||
based medical | multiple indications | |||||||||||
$200m/yr (Australia alone) | ||||||||||||
treatments | ||||||||||||
(CBMTs) | See ASX Announcement 19 October 2021 | |||||||||||
High-doseCBD for | ||||||||||||
EMD | -RX7 | |||||||||||
multiple indications | ||||||||||||
nal | [1] https://www.coherentmarketinsights.com/market-insight/post-traumatic-stress-disorder-treatment-market-4433 | |||||||||||
Next 3-6 months
- Complete pivotal trials
- TGA registration application
- New formulations
- Launch US registration programs
This is an excerpt of the original content. To continue reading it, access the original document here.